Articles

The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability. Why do some patients tolerate GLP-1 receptor agonists with ease while others discontinue early? Much like how individuals respond differently to diet or exercise, medication tolerance is influenced by a mix …

The rise of newer incretin-based therapies is changing how clinicians think about diabetes care. But are GLP-1 receptor agonists already being challenged by this next wave of incretin therapy? While these medications have transformed treatment in recent years, newer multi-agonist therapies are gaining attention. As a result, healthcare providers are …

Continuous ketone monitoring is gaining attention as a promising tool for detecting metabolic risk earlier than traditional methods. While glucose monitoring has long been the standard, ketones offer another layer of insight into how the body processes energy. Could this emerging technology reshape how clinicians assess risk and guide treatment …

What does success really look like with GLP-1 therapy in 2026? Is it simply lowering A1C, or are clinicians now aiming for something more sustainable like remission or long-term maintenance? As GLP-1 receptor agonists continue to transform diabetes care, the conversation is shifting beyond short-term outcomes. Today, defining clear and …

Why do some patients experience dramatic weight loss on GLP-1 therapies while others barely see a change? This question highlights growing interest in how patients respond differently to GLP-1 therapies, challenging the idea of “average” outcomes seen in clinical trials. While studies often report impressive results, real-world experiences show a …

GLP-1 dose escalation is quickly becoming a central topic in diabetes care, especially as higher dosing strategies gain traction. But are we truly entering a high-dose era, or simply refining how we use these powerful agents? As clinicians face patients who plateau on standard regimens, the question becomes not just …

Managing type 2 diabetes today can feel like navigating a moving target. As new guidelines shift toward personalized, risk-based care, many clinicians ask the same question: how can a diabetes risk stratification approach be applied effectively in daily practice? This evolving approach is not just theoretical. Instead, it offers a …

Why does clinical inertia diabetes continue to slow progress, even when better treatments are widely available? It is a bit like having a high-performance car but hesitating to press the accelerator. Despite major advances in medications and care models, delays in intensifying therapy remain common. As a result, many patients …

Interest in diabetes remission is growing in 2026, but is it realistic for everyone? As research evolves, clinicians are rethinking how and when to pursue remission as a treatment goal. While the idea of reversing type 2 diabetes is appealing, not every patient will benefit equally. This article explores the …

GLP-1 dose escalation is becoming a critical topic as demand for these therapies continues to surge. From semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro), these medications are reshaping diabetes and weight management. However, are clinicians and patients moving faster than the evidence supports? As real-world practices evolve, dosing strategies often stray …